Post-injury recovery
Tissue healing after acute injury — joints, tendons, ligaments, muscle tears, post-surgical recovery, chronic non-healing wounds.
Soft-tissue + tendon repair stack · 3 phases · guided multi-peptide program with decision criteria and add-to-stack handoff.
What changes during this transition
The library's strongest peptide-relevance use case. BPC-157 and TB-500 are the workhorses — both have meaningful animal data for tissue healing and substantial community use; both are Tier 3 in humans (animal data is the bulk of the evidence). IGF-1 LR3 has localized muscle-recovery applications. GHK-Cu addresses skin and connective tissue. CJC-1295 + Ipamorelin support recovery indirectly via GH/IGF-1. Combination protocols (BPC-157 + TB-500) are widely used despite no Phase III data — flag the evidence ceiling honestly.
Important caveat
Acute injuries should be evaluated by a clinician — peptides don't replace proper diagnostic workup (imaging, orthopedic assessment). Chronic pain or non-healing wounds deserve medical investigation before peptide adjuncts.
Peptides editorially relevant to post-injury recovery
6 peptides from the library — each evidence-tiered honestly.
- BPC-157Tier 3
Gastric pentadecapeptide
Extensively studied in rodents for tissue healing across tendon, gut, vascular, and CNS injury models. Human evidence is essentially absent — community framing far outpaces the data.
- TB-500Tier 3
Thymosin Beta-4 fragment
Animal-data peptide marketed as a tissue-repair adjunct. No published human RCTs for musculoskeletal indications.
- GHK-CuTier 2
Copper tripeptide
Strong topical evidence in skin and wound healing. Injectable systemic claims are an entirely different evidence base and tier.
- IGF-1 LR3Tier 3
IGF-1 analog (extended half-life, reduced IGFBP binding)
Bodybuilding community use. Tier 3 with serious safety flags: hypoglycemia from insulin-receptor cross-activity, unrestricted growth-tissue stimulation, theoretical cancer concerns. The evidence is thin and the risks are real.
- CJC-1295Tier 3
GHRH analog
Long-acting GHRH analog often paired with a GHRP. Strong PK data in humans; outcome data is limited.
- IpamorelinTier 3
GHRP / ghrelin mimetic
Selective GH-releasing peptide with minimal cortisol or prolactin elevation in early studies. Human outcome evidence is limited.
Want this list to grow? The library is editorial — if there’s a peptide you think belongs on this page with documented or mechanistically-clear evidence, send us a note with the citation and we’ll review it under the same evidence-tier discipline as every other entry.